ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
November 22, 2021BioNTech SE announced that the FDA granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma. -
mRNA-based therapeutic cancer vaccine enters Phase II trial
June 24, 2021BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo® (cemiplimab) for the treatment of melanoma.
Pharma Sources Insight January 2025
